当前位置: X-MOL 学术Schmerz › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Medizinalcannabis und cannabisbasierte Arzneimittel: ein Appell an Ärzte, Journalisten, Krankenkassen und Politiker für einen verantwortungsvollen Umgang
Der Schmerz ( IF 1.1 ) Pub Date : 2019-09-02 , DOI: 10.1007/s00482-019-00409-0
Winfried Häuser , Eva Hoch , Frank Petzke , Rainer Thomasius , Lukas Radbruch , Anil Batra , Claudia Sommer , Ursula Havemann-Reinecke

Since the adoption of the law of March 6, 2017, any German physician can prescribe medical cannabis flowers and cannabis-based magistral and finished medicinal products. No specific indications for prescriptions are provided in the law. The statutory health insurance companies bear the costs once an application for cost coverage has been approved by the Medical Service of the Health Funds. The German associations of psychiatry (child, adolescents, and adults), neurology, palliative care, addictology, and pain medicine are watching these developments in the media, politics, and medical world with concern due to: the option to prescribe cannabis flowers despite the lack of sound evidence and against the recommendations of the German Medical Association; the lack of distinction between medical cannabis flowers and cannabis-based magistral and finished medical products; the indiscriminately positive reports on the efficacy of cannabis-based medicines for chronic pain and mental disorders; the attempts by the cannabis industry to influence physicians; the increase in potential indications by leaders of medical opinion paid by manufacturers of cannabis-based medicines. The medical associations make the following appeal to journalists: To report on the medical benefits and risks of cannabis-based medicines in a balanced manner. To physicians: to prescribe cannabis-based medicines with caution; to prefer magistral and finished medicinal products over cannabis flowers. To politicians: to consider data according to the standards of evidence-based medicine when making decisions and provide financial support for medical research into cannabis-based medicines.

中文翻译:

医用大麻和基于大麻的药物:呼吁医生、记者、健康保险公司和政治家负责任地使用

自 2017 年 3 月 6 日法律通过以来,任何德国医生都可以开药用大麻花和以大麻为基础的药物和成品药。法律没有规定具体的处方说明。一旦健康基金的医疗服务部门批准了费用保险的申请,法定健康保险公司将承担费用。德国精神病学(儿童、青少年和成人)、神经病学、姑息治疗、成瘾学和止痛药协会正在关注媒体、政治和医学界的这些发展,因为:缺乏可靠的证据并违反德国医学会的建议;医用大麻花与基于大麻的地方法院和成品医疗产品之间缺乏区别;关于基于大麻的药物对慢性疼痛和精神障碍的疗效的不分青红皂白的积极报告;大麻产业试图影响医生;大麻药物制造商支付的医学意见领袖的潜在适应症增加。医学协会向记者发出以下呼吁: 以平衡的方式报道基于大麻的药物的医疗益处和风险。对医生:谨慎开出以大麻为基础的药物;与大麻花相比,更喜欢治安药和成品药。致政治家:
更新日期:2019-09-02
down
wechat
bug